CAP Derived Recombinant C1 Inhibitor Matches Berinert in Animal Study

CEVEC Pharmaceuticals, the developer and licensor of the CAP Technology, has announced a major milestone regarding its recombinant human CAP cell derived C1 Esterase Inhibitor (C1Inh).

CEVEC´s CAP derived C1 Inhibitor material showed in a pivotal pharmacokinetic rat study a serum half life matching one of the two currently available, plasma derived treatments, Berinert. All other known versions of recombinant C1 Inh, including, for example, Ruconest from transgenic rabbits, displayed so far a significantly shorter half life than plasma derived C1 Inh. To achieve this excellent protein quality of the recombinant C1Inh, new glycosylation optimized CAP-GO cells were developed at CEVEC. This result, in combination with previously shown excellent specific activities of CAP derived C1 Inh and commercially attractive production yields using CAP-GO cells, paves now the way to develop a safer and more economic therapy for acute and prophylactic HAE indications.

Dr Nicole Faust, CSO said: “A human cell derived recombinant C1 Inhibitor is a long sought after product as an alternative to the currently available plasma derived therapies. Our promising results based on our fully scalable and cGMP compliant CAP suspension cells potentially open an entire new way to treat HAE."

Wolfgang Kintzel, CEO comments: “We are proud to offer interested parties a licensable human cell derived recombinant C1 Inhibitor with safety and production advantages after years of intense development. We’re convinced that this molecule has the potential to become the recombinant alternative of choice in the HAE therapy field. CEVEC has an increasing license customer portfolio for its CAP cell lines. Additionally, we offer a variety of biotherapeutics in preclinical stage. CEVEC´s customers can now also order pre-clinical, Phase I and Phase II material via our CMO business."